




FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D




FIG. 2A




FIG. 2B




FIG. 3A




FIG. 3B




FIG. 3C

10/30




FIG. 4A




FIG. 4B

12/30




FIG. 4C




FIG. 5A




FIG. 5B




FIG. 6A




FIG. 6B




FIG. 7




FIG. 8A




FIG. 8B




FIG. 9




FIG. 10




FIG. 11




FIG. 12

Conjugate Dose (mg/kg)	Mean Liver Payload C _{max} (ng/g)	% Dose in Liver ¹
5 (0.125 mg)	60.8	~8%
10 (0.25 mg)	62.1	~4%
20 (0.5 mg)	122	~4%

¹ Estimated total amount of payload in liver vs. amount dosed on conjugate

FIG. 13




FIG. 14




FIG. 15

DAR	Conjugate Dose (mg/kg)	Payload C _{max} (ng/g)	% Dose in Liver ¹
2	0.5	13.9 (5.2, 23)	10
	2	191 (120, 260)	34
	6	834 (550, 1100)	50
4	0.1	63.8	~100
	0.5	192	74
	0.5	64.1 (37, 91)	25
	2	372 ²	36
	6	838 ³	27

¹Assuming 3 kg animal and payload ~1.2% and 0.64% of conjugate dose for DAR4 and DAR2, respectively
²2 and ³7 days post-dose - likely underestimate C_{max}

FIG. 16




FIG. 17




FIG. 18

NHP Dose Level	0.5 mg/kg (MPAD)	<2 mg/kg (BED)	6 mg/kg (Supra-Efficacious Dose)	Projected NOAEL ≥12 mg/kg
Mouse Equivalent Dose ¹ (ASGR1-TLR8 Surrogate)	10 mg/kg (0.25 mg)	20 mg/kg (0.5 mg)	–	–
Human Equivalent Dose ²	0.16 mg/kg	<0.65 mg/kg	1.9 mg/kg	≥3.9 mg/kg
Margin/Index ³	≥24 Safety Margin	≥12 Therapeutic Index ⁴	–	–

MPAD = Minimum Pharmacologically Active Dose; BED = Biologically Effective Dose; NOAEL = No Observed Adverse Effect Level

¹ Based on similar liver payload level to NHP dose; ² By standard allometric approach per FDA Guidance;

³ Relative to projected NOAEL of ≥12 mg/kg; ⁴ Assuming BED of 1 mg/kg

FIG. 19